HANG SENG is currently on bullish momentum. At 10:27 EST on Wednesday, 30 December, HANG SENG is at HK$27,147.11, 2.18% up since the last session's close.
HANG SENG Range
HANG SENG is 2.702% up from its last session low of HK$26,432.90 and 1.985% up from its last session high of HK$26,618.80.
Over the last three sessions, HANG SENG's higher value was HK$26,618.80 and the lower value was HK$26,221.30.
Over the last seven sessions, HANG SENG's higher value was HK$26,668.10 and the lower value was HK$25,998.90.
Over the last month, HANG SENG's higher value was HK$26,960.90 and the lower value was HK$25,998.90.
In relation to HANG SENG's yearly highs and lows, it's 28.42% up from its 52-week low and 6.95% down from its 52-week high.
Volatility
HANG SENG's last day, last week, and last month's average volatility was a positive 0.96%, a positive 0.20%, and a negative 0.06%, respectively.
HANG SENG's last day, last week, and last month's high and low average amplitude percentage was 0.70%, 1.01%, and 1.07%, respectively.
Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
